Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation

Abstract

Patients with Pompe disease have realized significant medical benefits due to enzyme replacement therapy (ERT) infusions with alglucosidase alfa. However, regular infusions are time-consuming. Utilizing recommended infusion rates, infusion duration is 3h 45min for a patient receiving the standard dose of 20mg/kg, not including additional time needed for preparation of ERT, assessment of vital signs, intravenous access, and post-infusion monitoring. Recent studies have demonstrated increased effectiveness of higher dose of ERT (40mg/kg) in infantile-onset Pompe disease (IOPD), which increases the infusion duration to 6h 36min. Increased infusion durations compound the psychosocial burden on patients and families and potentially further disrupt family activities and obligations. We developed a stepwise infusion rate escalation protocol to administer higher dose ERT safely while decreasing infusion duration, which has been implemented in 15 patients to date. Reported here in detail are five patients with IOPD on 40mg/kg/weekly ERT in whom infusion duration was decreased with individualized, stepwise rate escalation. All patients tolerated rate escalations above the recommended rates without experiencing any infusion associated reactions and experienced a reduction in infusion duration by 1h and 24min with a corresponding increase in reported satisfaction. Our experience with ERT rate escalation is presented.

Synopsis: A careful stepwise method of enzyme replacement therapy (ERT) rate escalation can safely reduce infusion duration in patients with Pompe disease.

Keywords: ERT; Enzyme replacement therapy; Glycogen storage disease type II; Infusion duration; Infusion rate escalation; Neuromuscular disease; Pompe disease.

Conflict of interest statement

Conflict of interest

AKD, CKW, HLC, ZBK, and SMD have no financial or proprietary interest in the materials presented herein.

Copyright © 2017 Elsevier Inc. All rights reserved.

Figures

Figure 1

Recommended and escalated infusion rates for patients with Pompe disease receiving ERT with alglucosidase alfa at dose of 40 mg/kg.